Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

llion.

"While, clearly the early part of 2009 produced disappointing clinical results for maribavir, 2008 was a very successful year for ViroPharma -- from strong financial results to great execution in all aspects of our business to the transformational acquisition of Lev Pharmaceuticals and the launch of Cinryze. As a result we believe we have positioned ourselves with a number of growth drivers and multiple opportunities for success," stated Vincent Milano, ViroPharma's president and chief executive officer. "Those who follow our company can look for a number of exciting milestones throughout the upcoming year, such as progress on Cinryze, including the ongoing commercial launch and our acute indication sBLA with a June PDUFA date; continued success with Vancocin; the planned initiation of clinical studies for NTCD; and continued strong financial performance."

Net sales of Vancocin were $50.0 million for the fourth quarter of 2008 and $232.3 million for the year ended December 31, 2008, as compared to $47.7 million and $203.8 million in the respective 2007 periods.

Operating income for the year ended December 31, 2008 was $78.7 million. Our operating loss for the fourth quarter 2008 was $3.4 million. These amounts are compared to operating income of $115.8 million and $19.0 million for the year and fourth quarter of 2007, respectively. Operating income decreased in both comparative periods primarily due to increased amortization expense, the growth in the investment in our pipeline and increased SG&A costs.

Net loss in the fourth quarter ended December 31, 2008 was $1.0 million, compared to net income of $20.4 million for the same period in 2007. For the twelve months ended December 31, 2008, net income was $67.6 million, compared to $95.4 million for the same period in 2007. Net loss per share for the quarter ended December 31, 2008 was $0.01 per share, basic and
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... 21, 2015 As part of its ... (BDWMC), Sun Health Foundation funded a $3.25 million project ... pharmacy with the most up-to-date features and technology. , ... The pharmacy's 45 staff members will begin moving from ... in the coming days. , The current pharmacy ...
(Date:5/20/2015)... FRANCISCO, Calif. , May 20, 2015 /PRNewswire/ ... ) today presented preliminary data demonstrating the ability ... idiopathic pulmonary fibrosis (IPF) from other interstitial lung ... findings suggest the classifier,s potential to help thousands ... to resolve ambiguity in IPF diagnosis – a ...
(Date:5/20/2015)... 20, 2015 The global genotyping market ... during the forecast period of 2015 to 2020 to ... used in drug discovery and development process and to ... In addition to this,heavy investments by key manufacturers to ... also propelling market growth. Browse 113 market data tables ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... environment and holding it indefinitely in molecular-sized containers has been ... say it represents a novel method of gas storage that ... safely and efficiently. , This is a proof of concept ... just improving on a method that already exists, said U ...
... First-String,Research, Inc. (FSR), a spin-off biotechnology company ... begun the human clinical trial,process for its unique, ... the "First in Man" trial will take place ... investors. Initial,preclinical studies have suggested the gel,s efficacy ...
... Feb. 1 Inverness Medical,Innovations, Inc. (Amex: ... press release dated January 31, 2008 and entitled ... Global Pharmaceutical,Biotechnology and Medical Device Conference on February ... of the Company,s presentation. The,correct time of the ...
Cached Biology Technology:Rounding up gases, nano-style 2MUSC Spin-Off Company to Test Regenerative Wound Healing Gel 2MUSC Spin-Off Company to Test Regenerative Wound Healing Gel 3
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... in 2004, found much higher levels of blindness than anticipated. ... the provision of health services in the region. , Sudan ... poorest in the world. The southern region of the country ... that went on for nearly half a century, with only ...
... the ocean to rescue a dying coral reef from destruction ... of comic-book superhero Batman, a batfish has saved a coral ... the fish was never previously known as a weed-eater. ... Coral Reef Studies (CoECRS) who were studying how coral reefs ...
... the dramatic increase in testicular cancer, now the ... is the focus of a five-year, $5.5 million ... Health researcher Tongzhang Zheng. , Testicular cancer is ... provide important information on possible environmental, genetic and ...
Cached Biology News:High levels of blindness in southern Sudan following years of war 2Batfish to the rescue! 2
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Proliferin (C-14)...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
Biology Products: